Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): β-Cryptoxanthin (βCX) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 1/November/2017, 11.33 pm

Molecular therapy for muscle atrophy and wasting:Rivaroxaban (Trade name: Xarelto), an anticoagulant (blood thinner), increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors  genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 1/November/2017, 4.33 am
October 31, 2017
Lifespan extension therapy:  4-Hydroxyderricin (4-HD), isolated from Ashitaba (Angelica Keiskei), increases life span via up-regulation of its target gene BubR1, 1/November/2017, 11.41 pm
November 1, 2017
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


 

From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based therapy for NAFLD. β-Criptoxanthin (βCX), by increasing the expression of its target gene, it may (1) promote degradation of HMGCR; and (2) suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing “β-Criptoxanthin (βCX) or its analogues, either alone or in combination with other drugs” may be used to treat NAFLD.

[easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how β-Criptoxanthin (βCX) decreases the expression of HMGCR to prevent progression to NAFLD

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does β-Criptoxanthin (βCX) decrease the expression of HMGCR to prevent progression of NAFLD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): β-Cryptoxanthin (βCX) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 1/November/2017, 11.33 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.